Biotechnology The National Institute for Health and Care Excellence has issued a final appraisal determination (FAD) recommending that AbbVie’s Venclyxto (venetoclax) be made available to National Health Service patients in England with difficult-to-treat types of chronic lymphocytic leukemia (CLL) via the Cancer Drugs Fund (CDF), providing conditions of the managed access agreement are followed. 5 October 2017